TCellRxDoc's profile picture. #CGAT@Dartmouth #EDIT@CGAT #DartmouthHemeOnc #DFCI #CART #BMT #OmicsinMedicine #Heterogeneityenthusiast, #genomicsinmedicine.tweets my own.  not org

Parth Shah MD

@TCellRxDoc

#CGAT@Dartmouth #EDIT@CGAT #DartmouthHemeOnc #DFCI #CART #BMT #OmicsinMedicine #Heterogeneityenthusiast, #genomicsinmedicine.tweets my own. not org

This is an important view point. Cancer is often an emotion and we are used to taking risks in cancer that we do not for most public health. Although I think MCED will at one point change healthcare - we CANNOT abandon the principles of screening tools.

Let's talk 🧵about the results of a new, large trial of a multi-cancer early detection blood test called Galleri, which costs $949, that enrolled 35,878 participants in the US and Canada aged 50+. Here is the registration: clinicaltrials.gov/study/NCT05155… These are the headlines

EricTopol's tweet image. Let's talk 🧵about the results of a new, large trial of a multi-cancer early detection blood test called Galleri, which costs $949, that enrolled 35,878 participants in the US and Canada aged 50+. Here is the registration: clinicaltrials.gov/study/NCT05155…
These are the headlines


Repost di Parth Shah MD

Highly recommended!! I did this fellowship last year and it was a perfect fit for me. Worth putting in the extra year. Gained a lot of amazing experience in MGCS, POEMS, AL with @ADispenzieri @MorieGertz @myelomaMD et al. Gave me time and mentorship to get grants/publications in.

Now Accepting Applications: Advanced Hematology Fellowship in Myeloma, amyloidosis & other plasma cell disorders @MayoClinic Rochester, MN!  1-year, dedicated training with stipend and benefits. @MorieGertz @Rfonsi1 @MayoMyeloma college.mayo.edu/academics/resi…



Repost di Parth Shah MD

Come work with us!! cc @MadhavDhodapkar @AJPortuguese @DimaDanai @RichaThakurMD and many more not on Twitter!

Fred Hutch is seeking a clinician-scholar committed to advancing leading-edge research and delivering world-class treatment in #multiplemyeloma and related plasma cell disorders. Learn more and apply: apply.interfolio.com/169136 #MMsm

fredhutch's tweet image. Fred Hutch is seeking a clinician-scholar committed to advancing leading-edge research and delivering world-class treatment in #multiplemyeloma and related plasma cell disorders. Learn more and apply: apply.interfolio.com/169136
#MMsm


Repost di Parth Shah MD

#Myeloma Paper of the Day: Eagerly awaited new high-risk IMWG definition: 1. del 17p w/ >20% clonal frac &/or TP53 mut; 2. t(4;14), t(14;16), t(14;20) w/ 1q+ &/or del 1p32; 3. monoallelic del 1p32 w/ 1q+ or biallelic del 1p32; 4. β2 ≥5.5 & nl SCr: pubmed.ncbi.nlm.nih.gov/40489728/. #mmsm

Myeloma_Doc's tweet image. #Myeloma Paper of the Day: Eagerly awaited new high-risk IMWG definition: 1. del 17p w/ >20% clonal frac &/or TP53 mut; 2. t(4;14), t(14;16), t(14;20) w/ 1q+ &/or del 1p32; 3. monoallelic del 1p32 w/ 1q+ or biallelic del 1p32; 4. β2 ≥5.5 & nl SCr: pubmed.ncbi.nlm.nih.gov/40489728/. #mmsm
Myeloma_Doc's tweet image. #Myeloma Paper of the Day: Eagerly awaited new high-risk IMWG definition: 1. del 17p w/ >20% clonal frac &/or TP53 mut; 2. t(4;14), t(14;16), t(14;20) w/ 1q+ &/or del 1p32; 3. monoallelic del 1p32 w/ 1q+ or biallelic del 1p32; 4. β2 ≥5.5 & nl SCr: pubmed.ncbi.nlm.nih.gov/40489728/. #mmsm
Myeloma_Doc's tweet image. #Myeloma Paper of the Day: Eagerly awaited new high-risk IMWG definition: 1. del 17p w/ >20% clonal frac &/or TP53 mut; 2. t(4;14), t(14;16), t(14;20) w/ 1q+ &/or del 1p32; 3. monoallelic del 1p32 w/ 1q+ or biallelic del 1p32; 4. β2 ≥5.5 & nl SCr: pubmed.ncbi.nlm.nih.gov/40489728/. #mmsm
Myeloma_Doc's tweet image. #Myeloma Paper of the Day: Eagerly awaited new high-risk IMWG definition: 1. del 17p w/ >20% clonal frac &/or TP53 mut; 2. t(4;14), t(14;16), t(14;20) w/ 1q+ &/or del 1p32; 3. monoallelic del 1p32 w/ 1q+ or biallelic del 1p32; 4. β2 ≥5.5 & nl SCr: pubmed.ncbi.nlm.nih.gov/40489728/. #mmsm

Clinical Implementation of Expanded Solid Tumor Fusion Detection With Whole-Transcriptome Sequencing at an Academic Cancer Center | JCO Precision Oncology ascopubs.org/doi/10.1200/PO… Awesome to see this finally out! More on the way to redefine molecular care !


Repost di Parth Shah MD

Interesting, I always wondered why heme biosynthesis comes up as a pathway involved in therapy resistance. Looks like it modulates apoptosis resistance.

Heme promotes venetoclax resistance, whereas inhibiting heme biosynthesis by targeting ferrochetalase, enhances venetoclax sensitivity. ow.ly/HW8e50UZPPy #lymphoidneoplasia #multiplemyeloma

BloodPortfolio's tweet image. Heme promotes venetoclax resistance, whereas inhibiting heme biosynthesis by targeting ferrochetalase, enhances venetoclax sensitivity. ow.ly/HW8e50UZPPy #lymphoidneoplasia #multiplemyeloma


Repost di Parth Shah MD

Thank you to everyone at @DartmouthCancer who supported this work, as well as @ASH_hematology for funding! @TCellRxDoc @TheBloodMD


Repost di Parth Shah MD

Congrats @RascheLeo et al for this excellent @BloodJournal work about better understanding EMD in #MMsm As a myeloma specialist, the ball of plasma cells in that visual abstract is more scary to me than the CML bunny will ever be!!! 😱

EMD mimics the architectural complexity of solid tumors, marked by diverse microenvironments, multiclonality, and TNFRSF17 and GPRC5D levels. ow.ly/kLji50U7uiz #lymphoidneoplasia #immunobiologyandimmunotherapy #multiplemyeloma

BloodPortfolio's tweet image. EMD mimics the architectural complexity of solid tumors, marked by diverse microenvironments, multiclonality, and TNFRSF17 and GPRC5D levels. ow.ly/kLji50U7uiz #lymphoidneoplasia #immunobiologyandimmunotherapy #multiplemyeloma


Repost di Parth Shah MD

Just out: Results of the CEPHEUS trial presented by @szusmani @MSKCancerCenter at the Plenary Session @Myeloma_Society Significant improvement in PFS with Dara-VRd compared to VRd in patients who were transplant ineligible or deferred. Median age 70. 1/

VincentRK's tweet image. Just out: Results of the CEPHEUS trial presented by @szusmani @MSKCancerCenter at the Plenary Session @Myeloma_Society

Significant improvement in PFS with Dara-VRd compared to VRd in patients who were transplant ineligible or deferred. Median age 70. 

1/

Repost di Parth Shah MD

Nice #MMsm work with provocative conclusion in @ASTCT_Journal by Wesson @DimaDanai @Abdallah81MD @hhashmi87 @NausheenAhmedMD and more! With so many "0%" incidences for new toxicities in weeks 3-4 following BCMA CAR-T, can 🇺🇸 REMS be shortened some day? sciencedirect.com/science/articl…

RahulBanerjeeMD's tweet image. Nice #MMsm work with provocative conclusion in @ASTCT_Journal by Wesson @DimaDanai @Abdallah81MD @hhashmi87 @NausheenAhmedMD and more!

With so many "0%" incidences for new toxicities in weeks 3-4 following BCMA CAR-T, can 🇺🇸 REMS be shortened some day?

sciencedirect.com/science/articl…

Repost di Parth Shah MD

This is the second of two back to back papers that show the value of belantamab in myeloma.

First of the @NEJM #ASCO24 myeloma papers that I will be highlighting. Congrats @dra_v_hungria @mvmateos @thanosdimop et al. nejm.org/doi/full/10.10…

VincentRK's tweet image. First of the @NEJM #ASCO24 myeloma papers that I will be highlighting. 

Congrats @dra_v_hungria @mvmateos @thanosdimop et al. nejm.org/doi/full/10.10…


Repost di Parth Shah MD

Second of the @NEJM #ASCO24 papers I’m highlighting. Congrats @thanosdimop nejm.org/doi/full/10.10…

VincentRK's tweet image. Second of the @NEJM #ASCO24 papers I’m highlighting. Congrats @thanosdimop 

nejm.org/doi/full/10.10…

Repost di Parth Shah MD

New IMS high risk definition for multiple myeloma presented by Prof Corre @COMyCongress . Fantastic effort by co-operative groups to redefine risk. Clearly an evolving area.

DrRakeshPopat's tweet image. New IMS high risk definition for multiple myeloma presented by Prof Corre @COMyCongress . Fantastic effort by co-operative groups to redefine risk. Clearly an evolving area.

Repost di Parth Shah MD

Dear @UHC: Ordering a PET scan for a high smoldering myeloma is critical! What u are doing is unacceptable and unethical for all myeloma Pts! Stop 🛑 Harming our patients by delaying their diagnosis! SHAME ON YOU @UHC #mmsm #myeloma #MedTwitter #MedEd


Repost di Parth Shah MD

This abstract relates to the FDA report on T cell lymphoma after CAR-T. Unfortunately it was not selected as an abstract for presentation at the ASH annual meeting and is an "online publication" only. @MoffittNews @MichaelDJain @ASH_hematology sciencedirect.com/science/articl…


Repost di Parth Shah MD

NEW—the final analysis of GRIFFIN showed that the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone in transplantation-eligible pts w/ newly diagnosed multiple myeloma improved depth of response and PFS, but not OS #mmsm thelancet.com/journals/lanha…

TheLancetHaem's tweet image. NEW—the final analysis of GRIFFIN showed that the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone in transplantation-eligible pts w/ newly diagnosed multiple myeloma improved depth of response and PFS, but not OS #mmsm thelancet.com/journals/lanha…
TheLancetHaem's tweet image. NEW—the final analysis of GRIFFIN showed that the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone in transplantation-eligible pts w/ newly diagnosed multiple myeloma improved depth of response and PFS, but not OS #mmsm thelancet.com/journals/lanha…

Repost di Parth Shah MD

🎶🎸🎹 Live now at the #IMWG: The Plasma Cells! #mmsm @VincentRK @paurotero @mvmateos @OcioEnrique

BrunoPaiva_UNAV's tweet image. 🎶🎸🎹  Live now at the #IMWG: The Plasma Cells!
#mmsm
@VincentRK @paurotero @mvmateos @OcioEnrique

Repost di Parth Shah MD

CAR-T Cells Manufactured With T-Charge Evaluated in R/R MM ashpublications.org/ashclinicalnew…


Loading...

Something went wrong.


Something went wrong.